Igyxos S.A. has completed a Series A fundraising
Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.
Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.
Oaklins’ team in France advised Igyxos on a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.
CSO and Founder, Igyxos, S.A.
Talk to the deal team
Thibaut de Monclin
Seniovo GmbH has been acquired by HORNBACH Baumarkt AG
The shareholders of Seniovo GmbH have sold the company to HORNBACH Baumarkt AG.Learn more
Nordian Capital has raised debt to acquire Wetac
Nordian Capital, a Netherlands-based private equity firm, has joined the shareholder base of Wetac Battery Company (Wetac), a leading supplier of batteries, battery systems and accessories for various applications and end markets. The financing was provided by OLB and will support Wetac’s strong growth ambitions.Learn more
Nordian joins the shareholder base of Wetac to support further growth
Nordian, a Netherlands-based private equity firm, has joined the shareholder base of Wetac, a leading supplier of batteries and battery systems for various applications and end markets.Learn more